Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the risk-benefit profile of ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

The FDA’s ODAC voted that data support the use of minimal residual disease as an end point to support accelerated approval of treatments in multiple myeloma.

Francesco Di Meo, PhD, discusses the rationale for targeting LILRB4 through CAR T-cell therapy in multiple myeloma.

Hans Lee, MD, discusses the rationale for the phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the optimal role for ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Linvoseltamab elicited responses with acceptable safety in patients with relapsed/refractory multiple myeloma, including difficult-to-treat subsets

The FDA has approved cilta-cel for select patients with relapsed/refractory multiple myeloma who have received at least 1 line of therapy, and who are lenalidomide refractory.

Danai Dima, MD, discusses real-world responses with teclistamab in relapsed/refractory multiple myeloma.

Krina K. Patel, MD, MSc, discusses the FDA approval of ide-cel for patients with triple class–exposed relapsed/refractory multiple myeloma.

The FDA has approved ide-cel (Abecma) for adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy.

Ariel Grajales-Cruz, MD, discusses the rationale for a real-world study of teclistamab in patients with myeloma who had received BCMA-directed therapy.

Rachid Baz, MD, discusses the importance of educating patients about potential adverse effects associated with multiple myeloma treatments.

Ricardo D. Parrondo, MD, discusses the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.

Joseph Mikhael, MD, discusses unmet needs that remain to be addressed in the treatment of patients with multiple myeloma.

Ariel Grajales-Cruz, MD, discusses research elucidating the role of teclistamab monotherapy for patients with relapsed/refractory multiple myeloma.

The European Commission has approved idecabtagene vicleucel for triple-class–exposed relapsed/refractory multiple myeloma.

Joshua Richter, MD, discusses ongoing or upcoming research with bispecific antibodies in relapsed/refractory multiple myeloma.

The FDA’s Oncologic Drugs Advisory Committee voted in favor of idecabtagene vicleucel for patients with early relapsed/refractory myeloma.

The FDA’s Oncologic Drugs Advisory Committee voted in favor of ciltacabtagene autoleucel for patients with early relapsed/refractory myeloma.

P-BCMA-ALLO1 has been granted orphan drug designation by the FDA for the treatment of patients with relapsed/refractory multiple myeloma.

Ariel F. Grajales-Cruz, MD, discusses the real-world efficacy of teclistamab in relapsed/refractory multiple myeloma.

Joshua Richter, MD, discusses the role of bispecific antibody therapy in myeloma and expands on toxicity management for these agents.

Joshua Richter, MD, FACP, presents recent National Comprehensive Cancer Network (NCCN) guideline updates in the treatment of multiple myeloma.

Sikander Ailawadhi, MD, discusses early efficacy and safety data for iopofosine I 131 monotherapy in Waldenström macroglobulinemia.

Ajai Chari, MD, discusses unmet needs in multiple myeloma, as well as what oncologists should know about the current treatment paradigm for this disease.